Service Communautaire d'Information sur la Recherche et le Développement - CORDIS

Application of the vector to the protection against human enteric and respiratory diseases. The vector is being applied to elicit protection against rotavirus infections

The vaccine developed for human rotaviruses still needs to be completed and its biosafety tested in the transgenic animal model developed. Other vaccines for animal health that have been used to improve the quality and biosafety of this type of vector could be ready in 24 months.

A candidate vaccine for SARS-CoV, based on a recombinant virus in which an structural gene has been deleted, is being tested in ferrets and monkeys for the moment, in collaboration with Dr. Albert Osterhaus (Rotherdam). If the results are satisfactory it may enter in preclinical trials in 1-2 years.

Reported by

CNB, CSIC
Campus Universidad Autonoma, Cantoblanco, Darwin 3
28049 Madrid
Spain